Global Markets Directs, 'Recurrent Malignant GliomaPipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Recurrent Malignant Glioma. Recurrent Malignant GliomaPipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

• A snapshot of the global therapeutic scenario for Recurrent Malignant Glioma.
• A review of the Recurrent Malignant Gliomaproducts under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Recurrent Malignant Gliomapipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

• Identify and understand important and diverse types of therapeutics under development for Recurrent Malignant Glioma.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Recurrent Malignant Gliomapipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Recurrent Malignant Glioma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Recurrent Malignant Glioma 10
Recurrent Malignant Glioma Therapeutics under Development by Companies 12
Recurrent Malignant Glioma Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Recurrent Malignant Glioma Therapeutics - Products under Development by Companies 19
Recurrent Malignant Glioma Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Recurrent Malignant Glioma Therapeutics Development 22
Boehringer Ingelheim GmbH 22
Eli Lilly and Company 23
Genentech, Inc. 24
Merck & Co., Inc. 25
Eisai Co., Ltd. 26
Oncolytics Biotech Inc. 27
BioNumerik Pharmaceuticals, Inc. 28
Recurrent Malignant Glioma - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
lenvatinib - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ridaforolimus - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Reolysin - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Perifosine + Temsirolimus - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Erlotinib + Sirolimus - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Arsenic Trioxide + Temozolomide + Radiation Therapy - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
AC-480 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
SU011248 + Irinotecan - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Enzastaurin + Bevacizumab - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
afatinib - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Avastin + Bortezomib - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Avastin + Temozolomide - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Avastin + Temozolomide - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Carboxyamidotriazole Orotate + Temodar - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
cositecan - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
aflibercept - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Zactima + Gleevec + Hydroxyurea - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 63
Bevacizumab + CPT-11 + Carboplatin - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
BIBW-2992 + Temozolomide - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Zactima + Etoposide - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
carmustine - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
DELTA-24-RGD-4C - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Bevacizumab + Irinotecan - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Bevacizumab + Radiation Therapy - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
paclitaxel - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Thymidine + Carboplatin - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Erlotinib Hydrochloride + Isotretinoin - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
sunitinib malate - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Bortezomib + Temozolomide - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Temozolomide + Vorinostat - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
AZD-7451 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
carmustine - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
temozolomide + cisplatin - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Recurrent Malignant Glioma Therapeutics - Drug Profile Updates 84
Recurrent Malignant Glioma Therapeutics - Discontinued Products 95
Recurrent Malignant Glioma Therapeutics - Dormant Products 96
Recurrent Malignant Glioma - Product Development Milestones 99
Featured News & Press Releases 99
Nov 15, 2012: DelMar Pharma To Present Interim Clinical Data On VAL-083 In Refractory Glioblastoma At SNO Annual Meeting 99

Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 102
Disclaimer 102